When Your Team Says "Chemo First" — And You Are Not Sure
You have metastatic castration-resistant prostate cancer, or mCRPC. You have been on hormone therapy for a while. One hormone treatment stopped working. Now your oncologist wants to try chemotherapy. You also heard about something called Lu-177 PSMA therapy. You are wondering if the order matters.
The short answer is yes. The order can matter. Asking for a second opinion about the order is a smart idea. It might be one of the most important steps you take right now.
Why Treatment Order Is a Real Medical Question
In cancer care, "sequencing" means the order of treatments. For men with mCRPC, the order has changed a lot in recent years.
For a long time, the standard path looked like this:
- Androgen deprivation therapy (ADT) — hormone injections or pills to lower testosterone
- One or two androgen receptor pathway inhibitors (ARPIs), such as enzalutamide or abiraterone
- Taxane-based chemotherapy, usually docetaxel, then sometimes cabazitaxel
- Lu-177 PSMA therapy — only after chemotherapy had already been tried and had not worked
That last point matters. For years, Lu-177 PSMA was only approved for men who finished both hormone therapy and chemotherapy. It was a later option. But the science changed. In 2025, the rules changed too.
The PSMAfore Trial Changed the Picture
The PSMAfore trial was a large international study. It included 468 men with PSMA-positive mCRPC who had progressed on one ARPI therapy. An important detail: none of them had yet received taxane-based chemotherapy. Doctors call this group "taxane-naïve."
Researchers compared two paths:
- Path A: Lu-177 PSMA therapy
- Path B: Switching to a different ARPI
The results came out at the American Society of Clinical Oncology (ASCO). Men in the Lu-177 PSMA group had no new cancer visible on scans for a median of 9.3 months. Men in the ARPI-switch group had no visible cancer growth for 5.6 months. The risk of cancer coming back was cut by more than half with Lu-177 PSMA (hazard ratio 0.41).
This showed that Lu-177 PSMA therapy may stop cancer growth better than switching ARPIs. This was true even before chemotherapy was used. It raised an important question: should some men get Lu-177 PSMA before chemotherapy?
What the FDA Decided in March 2025
Based on the PSMAfore data, the U.S. Food and Drug Administration expanded its approval of lutetium Lu 177 vipivotide tetraxetan in March 2025. According to the FDA's official announcement, the therapy is now approved for adults with PSMA-positive mCRPC who:
- Have already been treated with an androgen receptor pathway inhibitor (ARPI), and
- Are considered appropriate to delay taxane-based chemotherapy.
This is a big change. Lu-177 PSMA is no longer just a post-chemotherapy option. For men who meet these criteria, it can now be used before chemotherapy. The Prostate Cancer Foundation explains this change in plain language. It's a good resource to share with your care team.
If your oncologist is recommending chemotherapy first and hasn't talked about this expanded approval or the PSMAfore data in your plan, that's a good reason to get another opinion.
Why Would a Doctor Still Recommend Chemo First?
Your doctor may have good medical reasons for recommending chemotherapy first. This doesn't mean they're wrong. Some valid reasons include:
- Tumor biology. If your PSMA PET scan shows low or inconsistent PSMA expression across your tumor sites, Lu-177 PSMA may not work as well. Chemotherapy works even without PSMA expression.
- Disease pace. If your cancer is growing quickly or causing serious symptoms, your doctor may think chemotherapy will control it faster.
- Center availability. Not all hospitals offer Lu-177 PSMA therapy. Your doctor may suggest what's available at your hospital.
- Access or insurance. In some places, insurance limits or logistics affect which therapies are offered first.
- Older information. Medicine changes slowly. Some oncologists may still use treatment plans from before the 2025 FDA approval and PSMAfore results.
None of these reasons are shameful. But they show why a second, independent expert review is so valuable.
What "Appropriate to Delay Chemotherapy" Actually Means
The FDA's expanded approval uses a key phrase: "appropriate to delay taxane-based chemotherapy." This is not a blanket approval for everyone. It depends on your specific situation. Factors that support using Lu-177 PSMA before chemotherapy can include:
- Strong PSMA expression on your PET scan
- Adequate kidney and bone marrow function
- No prior taxane-based chemotherapy
- Slower cancer growth that gives time for a targeted approach
- You and your doctor both want to keep chemotherapy as a future option
A specialist in radioligand therapy can assess these factors. This might be a nuclear medicine doctor, a radiation oncologist with RLT experience, or an oncologist at a center that does PSMA therapy regularly. If your current team hasn't talked to such a specialist, it's worth getting a second opinion.
To understand the eligibility criteria in more detail, see our guide: Am I a Candidate for Lu-177 PSMA Therapy? A Plain-Language Guide for Men with mCRPC.
A Second Opinion Is Not Disloyal
Many patients worry that asking for a second opinion will upset their doctor, slow things down, or show distrust. These feelings make sense. But in oncology, second opinions are routine and respected. They're especially important for complex sequencing decisions.
A second opinion on mCRPC sequencing is particularly worth pursuing when:
- A newer therapy or expanded approval may not be in your current plan yet
- You haven't received chemotherapy yet and want to understand all options before starting
- Your PSMA PET scan results haven't been fully discussed for sequencing
- You're being treated at a community hospital rather than an academic or NCI-designated cancer center
- Your research or conversations with other patients raised questions you haven't asked yet
The Prostate Cancer Foundation says PSMA-targeted radioligand therapy is a fast-changing field. Expert second opinions are important, especially from centers with RLT experience. Seeking that review doesn't reject your current team. It helps you understand your options better.
What to Bring and What to Ask
A good second opinion for mCRPC sequencing should come from a team with radioligand therapy experience. When you go, bring:
- Your most recent PSMA PET scan images and the written radiology report
- Your complete treatment history — every therapy tried, in order, with approximate dates
- Your most recent PSA levels and full blood lab results
- Any genetic or molecular testing results, such as BRCA2, ATM, or HRR panel findings
- A list of your current medications and supplements
Ask these questions directly:
- "Based on my PSMA scan and treatment history, am I eligible for Lu-177 PSMA therapy before chemotherapy?"
- "What does the PSMAfore trial data suggest for someone in my situation?"
- "If I do Lu-177 PSMA first, can I still receive chemotherapy later if I need it?"
- "Does prior taxane chemotherapy affect PSMA expression — could chemo first reduce my chances of qualifying for Lu-177 PSMA afterward?"
- "Are there any clinical trials studying earlier use of Lu-177 PSMA that I should know about?"
That last question about chemotherapy and PSMA expression is important to ask. Early research suggests that taxane chemotherapy might affect PSMA uptake in some patients. This is still being studied. It's one reason some specialists prefer Lu-177 PSMA before chemotherapy in eligible men. It helps keep the tumor a good target for the radioligand.
What If Both Teams Agree?
If a second expert also recommends chemotherapy first, that's still helpful. You will know the recommendation was reviewed by an independent expert. You can move forward with more confidence. A confirmed plan is better than one you just accepted.
The second team might also agree on the general direction but suggest a different path in between. This could be a clinical trial, PARP inhibitor testing if you carry a BRCA mutation, or a different sequencing approach.
If you want to understand what other options may exist when hormone therapy has already stopped working, our related article covers this in depth: My Prostate Cancer Stopped Responding to Hormone Therapy — What Are My Options Before Chemotherapy?
The Bottom Line: You Have the Right to Ask "Why This Order?"
Treatment sequencing in mCRPC is no longer a fixed ladder you climb one rung at a time. The field has changed. New data from studies like PSMAfore and the FDA's 2025 expanded approval mean the best path forward depends on your specific tumor, scan results, overall health, and which expert is reviewing the evidence.
Asking "why chemotherapy before Lu-177 PSMA?" is a smart, medically valid question. It shows you're an active participant in your own care. That engagement matters.
For a deeper look at what the PSMAfore results mean specifically for patients like you, see our summary: PSMAfore: Lu-177 PSMA Therapy Before Chemotherapy Shows Benefit.
You deserve to understand what treatment you are receiving and why. You also deserve to know if the timing is truly the best option for you.
When to Talk to Your Doctor
If chemotherapy has been recommended as your next step and you haven't started taxane-based chemo yet, talk directly with your oncologist about your PSMA PET scan results. Ask whether Lu-177 PSMA therapy before chemotherapy is appropriate for you. Ask whether your team includes a nuclear medicine specialist with radioligand therapy experience. If not, ask for a referral to a center that does. This conversation doesn't replace your relationship with your current team. It can make your plan stronger.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
Frequently asked questions
Does the order of treatments really matter for mCRPC?
Yes, it can. The PSMAfore trial showed that giving Lu-177 PSMA therapy before taxane chemotherapy may delay disease progression more effectively than switching to another hormone-blocking drug in taxane-naïve men with mCRPC. In March 2025, the FDA expanded its approval to allow Lu-177 PSMA to be used before chemotherapy in patients who are considered appropriate to delay taxane-based treatment. Your specific scan results, treatment history, and overall health all affect which order makes most sense for you — which is why getting an expert review of your sequencing is so worthwhile.
What does "taxane-naïve" mean, and am I considered that?
Taxane-naïve means you have never received a taxane-based chemotherapy drug, such as docetaxel or cabazitaxel. If you have been on hormone therapy and androgen receptor pathway inhibitors but have not yet had chemotherapy for your metastatic prostate cancer, you are likely taxane-naïve. This matters because the FDA's 2025 expanded approval for Lu-177 PSMA before chemotherapy applies specifically to men in this group — those who have received an ARPI and for whom delaying taxane therapy is considered medically appropriate.
Will asking for a second opinion delay my treatment dangerously?
A second opinion usually takes one to two weeks to arrange at most cancer centers. In most cases, this short window does not harm outcomes. In fact, the time spent getting the right treatment sequence can be far more valuable than starting the wrong one immediately. That said, every case is different. If your oncologist believes your disease is progressing rapidly and urgency is a real medical concern, they will tell you — and that context should factor into your timing. Ask them directly: "How quickly do I need to start treatment, and does a short delay for a second opinion carry a medical risk for me?"
How do I find a center that offers Lu-177 PSMA therapy and can evaluate my sequencing?
Lu-177 PSMA therapy is offered at NCI-designated comprehensive cancer centers, academic medical centers, and some community centers with nuclear medicine programs experienced in radioligand therapy. Your current oncologist can provide a referral, or you can contact the Prostate Cancer Foundation at pcf.org for resources to help identify centers with RLT expertise. When calling to book a second opinion appointment, ask specifically whether the center has a nuclear medicine physician who participates in Lu-177 PSMA therapy decisions — not just a medical oncologist alone.
If my PSMA PET scan was done more than six months ago, do I need a new one before a second opinion?
PSMA expression on tumors can change over time, particularly after additional lines of therapy. If your most recent PSMA PET scan is older than approximately six months, the second-opinion team may want to order a fresh scan before making recommendations about your eligibility for Lu-177 PSMA therapy. Raise this when you contact the center to book your appointment — ask whether they need updated imaging and whether they can order or arrange the scan as part of the consultation process.
If I do chemotherapy first, can I still get Lu-177 PSMA therapy afterward?
Lu-177 PSMA was originally approved for use after both hormone therapy and taxane-based chemotherapy, so going through chemo first does not necessarily close the door on Lu-177 PSMA later. However, early research has raised the possibility that prior taxane therapy may affect PSMA expression in some patients, potentially making them less likely to qualify for — or respond as well to — radioligand therapy afterward. This is one reason some specialists now prefer to explore Lu-177 PSMA before chemotherapy for eligible men. This is exactly the kind of question a second opinion team specializing in radioligand therapy can address for your specific case.